Cargando…

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Despite years of clinical progress which made Hodgkin lymphoma (HL) one of the most curable malignancies with conventional chemotherapy, refractoriness and recurrence may still affect up to 20–30% of patients. The revolution brought by the advent of immunotherapy in all kinds of neoplastic disorders...

Descripción completa

Detalles Bibliográficos
Autores principales: Hazane Leroyer, Esther, Ziegler, Caroline, Moulin, Charline, Campidelli, Arnaud, Jacquet, Caroline, Rubio, Marie Thérèse, Feugier, Pierre, Pagliuca, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656939/
https://www.ncbi.nlm.nih.gov/pubmed/36362802
http://dx.doi.org/10.3390/jcm11216574
_version_ 1784829564915023872
author Hazane Leroyer, Esther
Ziegler, Caroline
Moulin, Charline
Campidelli, Arnaud
Jacquet, Caroline
Rubio, Marie Thérèse
Feugier, Pierre
Pagliuca, Simona
author_facet Hazane Leroyer, Esther
Ziegler, Caroline
Moulin, Charline
Campidelli, Arnaud
Jacquet, Caroline
Rubio, Marie Thérèse
Feugier, Pierre
Pagliuca, Simona
author_sort Hazane Leroyer, Esther
collection PubMed
description Despite years of clinical progress which made Hodgkin lymphoma (HL) one of the most curable malignancies with conventional chemotherapy, refractoriness and recurrence may still affect up to 20–30% of patients. The revolution brought by the advent of immunotherapy in all kinds of neoplastic disorders is more than evident in this disease because anti-CD30 antibodies and checkpoint inhibitors have been able to rescue patients previously remaining without therapeutic options. Autologous hematopoietic cell transplantation still represents a significant step in the treatment algorithm for chemosensitive HL; however, the possibility to induce complete responses after allogeneic transplant procedures in patients receiving reduced-intensity conditioning regimens informs on its sensitivity to immunological control. Furthermore, the investigational application of adoptive T cell transfer therapies paves the way for future indications in this setting. Here, we seek to provide a fresh and up-to-date overview of the new immunotherapeutic agents dominating the scene of relapsed/refractory HL. In this optic, we will also review all the potential molecular mechanisms of tumor resistance, theoretically responsible for treatment failures, and we will discuss the place of allogeneic stem cell transplantation in the era of novel therapies.
format Online
Article
Text
id pubmed-9656939
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96569392022-11-15 Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma Hazane Leroyer, Esther Ziegler, Caroline Moulin, Charline Campidelli, Arnaud Jacquet, Caroline Rubio, Marie Thérèse Feugier, Pierre Pagliuca, Simona J Clin Med Review Despite years of clinical progress which made Hodgkin lymphoma (HL) one of the most curable malignancies with conventional chemotherapy, refractoriness and recurrence may still affect up to 20–30% of patients. The revolution brought by the advent of immunotherapy in all kinds of neoplastic disorders is more than evident in this disease because anti-CD30 antibodies and checkpoint inhibitors have been able to rescue patients previously remaining without therapeutic options. Autologous hematopoietic cell transplantation still represents a significant step in the treatment algorithm for chemosensitive HL; however, the possibility to induce complete responses after allogeneic transplant procedures in patients receiving reduced-intensity conditioning regimens informs on its sensitivity to immunological control. Furthermore, the investigational application of adoptive T cell transfer therapies paves the way for future indications in this setting. Here, we seek to provide a fresh and up-to-date overview of the new immunotherapeutic agents dominating the scene of relapsed/refractory HL. In this optic, we will also review all the potential molecular mechanisms of tumor resistance, theoretically responsible for treatment failures, and we will discuss the place of allogeneic stem cell transplantation in the era of novel therapies. MDPI 2022-11-06 /pmc/articles/PMC9656939/ /pubmed/36362802 http://dx.doi.org/10.3390/jcm11216574 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hazane Leroyer, Esther
Ziegler, Caroline
Moulin, Charline
Campidelli, Arnaud
Jacquet, Caroline
Rubio, Marie Thérèse
Feugier, Pierre
Pagliuca, Simona
Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma
title Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma
title_full Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma
title_fullStr Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma
title_full_unstemmed Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma
title_short Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma
title_sort filling the gap: the immune therapeutic armamentarium for relapsed/refractory hodgkin lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656939/
https://www.ncbi.nlm.nih.gov/pubmed/36362802
http://dx.doi.org/10.3390/jcm11216574
work_keys_str_mv AT hazaneleroyeresther fillingthegaptheimmunetherapeuticarmamentariumforrelapsedrefractoryhodgkinlymphoma
AT zieglercaroline fillingthegaptheimmunetherapeuticarmamentariumforrelapsedrefractoryhodgkinlymphoma
AT moulincharline fillingthegaptheimmunetherapeuticarmamentariumforrelapsedrefractoryhodgkinlymphoma
AT campidelliarnaud fillingthegaptheimmunetherapeuticarmamentariumforrelapsedrefractoryhodgkinlymphoma
AT jacquetcaroline fillingthegaptheimmunetherapeuticarmamentariumforrelapsedrefractoryhodgkinlymphoma
AT rubiomarietherese fillingthegaptheimmunetherapeuticarmamentariumforrelapsedrefractoryhodgkinlymphoma
AT feugierpierre fillingthegaptheimmunetherapeuticarmamentariumforrelapsedrefractoryhodgkinlymphoma
AT pagliucasimona fillingthegaptheimmunetherapeuticarmamentariumforrelapsedrefractoryhodgkinlymphoma